[{"orgOrder":0,"company":"IASO Bio","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"IASO Bio","amount2":0.16,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Cabaletta Bio","highestDevelopmentStatusID":"4","companyTruncated":"IASO Bio \/ Cabaletta Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"IBI326","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ IASO Bio","highestDevelopmentStatusID":"8","companyTruncated":"IASO Bio \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"Undisclosed","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ IASO Bio","highestDevelopmentStatusID":"1","companyTruncated":"IASO Bio \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Sana Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Sana Biotechnology"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Shanghai Guoxin Investment & Development","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Series C Financing","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Shanghai Guoxin Investment & Development","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Shanghai Guoxin Investment & Development"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CT103A","moa":"BCMA receptor","graph1":"Immunology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CT103A","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CT103A","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT103A","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IASO-782","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IASO-782","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IASO-782","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Merck & Co"},{"orgOrder":0,"company":"IASO Bio","sponsor":"The First Affiliated Hospital with Nanjing Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"UB-VV400","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ The First Affiliated Hospital with Nanjing Medical University","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ The First Affiliated Hospital with Nanjing Medical University"},{"orgOrder":0,"company":"IASO Bio","sponsor":"The First Affiliated Hospital with Nanjing Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"UB-VV410","moa":"CD22","graph1":"Immunology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ The First Affiliated Hospital with Nanjing Medical University","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ The First Affiliated Hospital with Nanjing Medical University"},{"orgOrder":0,"company":"IASO Bio","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT125A","moa":"CD5","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT125A","moa":"CD5","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IASO Bio \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Ruijin Hospital, Shanghai Jiao Tong University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CAR-GPRC5D T Cell","moa":"GPRC5D","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Ruijin Hospital, Shanghai Jiao Tong University","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ Ruijin Hospital, Shanghai Jiao Tong University"},{"orgOrder":0,"company":"IASO Bio","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CAR-GPRC5D T Cell","moa":"GPRC5D","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"RD118","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"CDH Baifu","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Series C Financing","leadProduct":"RD126","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"IASO Bio","amount2":0.11,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ CDH Baifu","highestDevelopmentStatusID":"4","companyTruncated":"IASO Bio \/ CDH Baifu"},{"orgOrder":0,"company":"IASO Bio","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"RD133","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"RD133","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Umoja Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ IASO Bio","highestDevelopmentStatusID":"2","companyTruncated":"IASO Bio \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Umoja Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ IASO Bio","highestDevelopmentStatusID":"3","companyTruncated":"IASO Bio \/ IASO Bio"}]

Find Clinical Drug Pipeline Developments & Deals by IASO Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Lead Product(s) : UB-VV410

                          Therapeutic Area : Immunology

                          Study Phase : Phase I

                          Sponsor : The First Affiliated Hospital with Nanjing Medical University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : UB-VV410 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          August 07, 2025

                          Lead Product(s) : UB-VV410

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : The First Affiliated Hospital with Nanjing Medical University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Equecabtagene Autoleucel is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Immunoglobulin Light-chain Amyloidosis.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          July 09, 2025

                          Lead Product(s) : Equecabtagene Autoleucel

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Fucaso (equecabtagene autoleucel) is a BCMA chimeric antigen receptor autologous T cell therapy, being investigated for the treatment of Relapsed/Refractory Multiple Myeloma.

                          Product Name : Fucaso

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          May 09, 2025

                          Lead Product(s) : Equecabtagene Autoleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Equecabtagene Autoleucel is a Cell and Gene Therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Lupus Erythematosus, Systemic.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          March 30, 2025

                          Lead Product(s) : Equecabtagene Autoleucel

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Recipient : Tongji Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Fucaso (equecabtagene autoleucel) is a BCMA chimeric antigen receptor autologous T cell therapy, being investigated for the treatment of Relapsed/Refractory Multiple Myeloma.

                          Product Name : Fucaso

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          March 28, 2025

                          Lead Product(s) : Equecabtagene Autoleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Fucaso (equecabtagene autoleucel) is a BCMA chimeric antigen receptor autologous T cell therapy, being investigated for the treatment of Relapsed/Refractory Multiple Myeloma.

                          Product Name : Fucaso

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          February 14, 2025

                          Lead Product(s) : Equecabtagene Autoleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Fucaso (equecabtagene autoleucel) is a BCMA chimeric antigen receptor autologous T cell therapy, being investigated for the treatment of Relapsed/Refractory Multiple Myeloma.

                          Product Name : Fucaso

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          January 29, 2025

                          Lead Product(s) : Equecabtagene Autoleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Lead Product(s) : UB-VV400

                          Therapeutic Area : Oncology

                          Study Phase : Phase I

                          Sponsor : The First Affiliated Hospital with Nanjing Medical University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : UB-VV400 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          December 20, 2024

                          Lead Product(s) : UB-VV400

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : The First Affiliated Hospital with Nanjing Medical University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Fucaso (equecabtagene autoleucel) is a BCMA chimeric antigen receptor autologous T cell therapy, being investigated for the treatment of Non-renal Systemic Lupus Erythematosus.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          August 12, 2024

                          Lead Product(s) : Equecabtagene Autoleucel

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : IASO-782 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Purpura, Thrombocytopenic, Idiopathic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 01, 2024

                          Lead Product(s) : IASO-782

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank